Novartis/$NVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Employees
75,883
Headquarters
Basel, Switzerland
Website
Novartis Metrics
BasicAdvanced
$237B
16.80
$7.30
0.57
$2.60
2.12%
Price and volume
Market cap
$237B
Beta
0.57
52-week high
$133.55
52-week low
$96.06
Average daily volume
1.7M
Dividend rate
$2.60
Financial strength
Current ratio
0.881
Quick ratio
0.583
Long term debt to equity
54.161
Total debt to equity
71.554
Dividend payout ratio (TTM)
54.32%
Interest coverage (TTM)
18.35%
Profitability
EBITDA (TTM)
24,923
Gross margin (TTM)
76.25%
Net profit margin (TTM)
25.53%
Operating margin (TTM)
36.29%
Effective tax rate (TTM)
12.40%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
12.13%
Return on equity (TTM)
32.62%
Valuation
Price to earnings (TTM)
16.798
Price to revenue (TTM)
4.256
Price to book
4.28
Price to tangible book (TTM)
-18.5
Price to free cash flow (TTM)
13.991
Free cash flow yield (TTM)
7.15%
Free cash flow per share (TTM)
8.763
Dividend yield (TTM)
2.12%
Forward dividend yield
2.12%
Growth
Revenue change (TTM)
12.88%
Earnings per share change (TTM)
-14.91%
3-year revenue growth (CAGR)
7.00%
10-year revenue growth (CAGR)
1.08%
3-year earnings per share growth (CAGR)
-9.39%
10-year earnings per share growth (CAGR)
-0.19%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Bulls say / Bears say
Novartis raised its full-year 2025 earnings outlook, increasing its core operating income growth target to the low-teens range from the previous low-double-digits, following a strong Q2. (Reuters)
In June 2025, Novartis announced that Pluvicto’s late-stage PSMAddition trial achieved its primary goal by demonstrating a clinically meaningful improvement in progression-free survival for patients with metastatic hormone-sensitive prostate cancer, supporting a possible regulatory expansion in H2 2025. (Reuters)
Novartis received a positive CHMP opinion for Piqray in HR+/HER2- advanced breast cancer patients with PIK3CA mutations. Phase III data showed nearly double median progression-free survival, 11.0 months versus 5.7 months, significantly strengthening its oncology portfolio. (Reuters)
Sales of Cosentyx fell short of expectations, and increased generic competition reduced Q2 growth by two percentage points, showing ongoing challenges in Novartis’s established brands. (Reuters)
Novartis could face civil or criminal penalties after admitting data manipulation in its Zolgensma gene therapy program, exposing it to legal and reputational risks. (Reuters)
Pursuing both a $10 billion share buyback and a $23 billion U.S. manufacturing expansion could pressure Novartis’s free cash flow and reduce its financial flexibility for future R&D. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $237B as of October 31, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 16.8 as of October 31, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of October 31, 2025, the dividend rate is $2.59609 and the yield is 2.12%. Novartis has a payout ratio of 54.32% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.